What is Seaport Therapeutics 's D&A?

Seaport Therapeutics (SPTX) reported D&A of $26K in Q1 2026.

Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.

Seaport Therapeutics SPTX D&A

D&A at other companies

MYR GroupMYRG

$16.55M+10.3%

NNN REITNNN

$70.8M+9.6%

Piper SandlerPIPR

$4.73M+12.4%

RepligenRGEN

$19.76M+5.7%

American Healthcare REITAHR

$67.06M+63.1%

LKQLKQ

$99M-1.0%

Other financials

Income statement

See full

Operating income-$27.5M-70.2%

Net income-$25.4M-93.6%

EPS (diluted)-$10.34-83.0%

Balance sheet

See full

Cash & equivalents$52.9M—

Total debt$5.3M—

Total equity-$115.6M-220%

Total assets$227.7M—

Cash flow

See full

Operating cash flow-$20.2M+0.2%

CapEx--100%

Free cash flow-$20.2M+0.4%

Valuation

See full

Market cap$972.65M—

Enterprise value$925.08M—

Returns & leverage

See full

Debt / equity-0×—

Current ratio13.2×—

Where this comes from

Reported directly by Seaport Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: Seaport Therapeutics ’s 10-Q, filed June 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Seaport Therapeutics 's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Seaport Therapeutics 's D&A?: Seaport Therapeutics (SPTX) reported D&A of $26K in Q1 2026.
What does D&A mean?: Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.